Company news

Evofem Biosciences, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Evofem Biosciences Adds Additional Manufacturing Capacity for PHEXX® to Support Global Growth Strategy

September 23, 2026

Evofem Biosciences Celebrates Shipment of Its 500,000th Unit of PHEXX®, Representing Hormone-Free Protection from Unintended Pregnancy for 6 Million Acts of Sex

July 23, 2026

Evofem Reports First Quarter 2026 Financial Results and Provides Business Update

May 18, 2026

Evofem Announces Exclusive Agreement for the Distribution and Commercialization of SOLOSEC in Sub-Saharan Africa

April 27, 2026

Evofem Reports Fifth Consecutive Year of Net Sales Growth

March 11, 2026

Evofem CEO Saundra Pelletier Calls for a "Ground-Up Reset" of Women’s Health at Fierce JPM Week 2026

January 23, 2026

Evofem Expands "Say Vagina" Campaign With Launch of Say Vagina Store

January 21, 2026

Favorable Pricing Certificates Issued for Evofem's PHEXX by Emirates Drug Establishment are Launching Step for Commercialization in UAE

November 21, 2025

Evofem Reports Financial Results for Third Quarter of 2025, Provides Business Update

November 13, 2025

Evofem Announces Voting Results from Special Meeting of Stockholders

October 20, 2025

Evofem's SOLOSEC Submitted for Marketing Approval in United Arab Emirates

October 1, 2025

Evofem Biosciences Honors World Contraception Day

September 26, 2025

Evofem's "Say Vagina" Campaign Generates More than 2.5 Million Views Across Social Media Platforms

September 11, 2025

Evofem Anticipates Approval of Merger with Aditxt at Upcoming Stockholder Meeting

September 9, 2025

Illinois Pharmacists Can Prescribe PHEXXI Starting January 2026 Under Newly-passed Law

August 21, 2025

FDA Orange Book Lists New U.S. Patent for SOLOSEC, Evofem Biosciences' "One and Done" Oral Treatment for Bacterial Vaginosis and Trichomoniasis

August 19, 2025

Evofem Reports Positive Financial Results for Second Quarter of 2025, Provides Business Update

August 14, 2025

Evofem CEO Saundra Pelletier Honored with Trailblazing Female Founders Award at STIMULATE Conference

August 5, 2025

Phexxi -- A Non-Hormonal Birth Control Brand -- Goes Viral with Microfeminism on TikTok, Featured by BuzzFeed and Scary Mommy

July 15, 2025

Evofem's PHEXXI Submitted for Marketing Approval in United Arab Emirates by Pharma 1 Drug Store

June 23, 2025

Notable Data on Evofem's SOLOSEC in Recurrent Bacterial Vaginosis (BV) Released at ACOG Annual Meeting

June 11, 2025

Evofem Signs SOLOSEC License Agreement for Middle East with Pharma 1

May 21, 2025

Evofem Reports First Quarter 2025 Financial Results and Provides Business Update

May 15, 2025

Presenting on Emerging Growth Conference 81 Day 2 on April 17; Register to live stream

April 15, 2025

Windtree Therapeutics Reports Year-End 2024 Financial Results and Provides Key Business Updates

April 14, 2025

Evofem Biosciences to Present at Emerging Growth Conference

April 14, 2025

Evofem Expects Significant Reduction in PHEXXI Manufacturing Cost Through Agreement with Windtree Therapeutics

March 26, 2025

Evofem Reports Fourth Consecutive Year of Net Sales Growth

March 24, 2025

Evofem Strengthens SOLOSEC Intellectual Property with New U.S. Patent from USPTO

February 12, 2025

Evofem Biosciences Announces Financial Results for the Third Quarter of 2024

November 13, 2024

Aditxt Provides Update on Equity Line of Credit, ATM Usage, and Outstanding Number of Shares

November 7, 2024

Aditxt Acquisition Target Evofem Biosciences Secures Investor Support Through Voting Agreements for Merger with Aditxt's Subsidiary Adifem

November 5, 2024

Evofem Secures Investor Support for Proposed Merger through Voting Agreements

November 5, 2024

Aditxt To Host Virtual Stakeholder Update and Q&A Session on Friday, November 1, 2024, at 11: 30 AM Eastern Time

October 29, 2024

Sylvia Hermina Joins Aditxt’s Board of Directors, Elevating Leadership with Broader Perspectives

October 28, 2024

Aditxt Completes Final Equity Investment and Key Milestone Under the Amended and Restated Merger Agreement with Evofem

October 27, 2024

Aditxt to Host a Virtual Fireside Chat with Aditxt CEO Amro Albanna and Evofem CEO Saundra Pelletier, Moderated by MD & Media Personality Dr. Drew Pinsky, on October 28, 2024, at 11: 30 AM Eastern Time

October 20, 2024

Aditxt Completes Third Parent Equity Investment Under Amended and Restated Merger Agreement With Evofem

October 7, 2024

Aditxt Delivers Shareholder Update and 2024 Year-End Plan

October 2, 2024

Evofem Biosciences Files Preliminary Proxy for Stockholder Approval of the Acquisition by Aditxt

September 23, 2024

Aditxt’s Subsidiary Pearsanta to Collaborate with Evofem Biosciences for Targeted U.S. Launch of Endometriosis Diagnostic in Mid-2025

September 19, 2024

Aditxt and Evofem Sign Second Amendment to Amended and Restated Merger Agreement, Target Closing of Acquisition in Fourth Quarter of 2024

September 8, 2024

Aditxt to Present at the H.C. Wainwright 26th Annual Global Investment Conference September 9th-11th, 2024

August 28, 2024

Evofem Biosciences Addresses the Impact of GLP-1 Medications on Oral Contraceptive Absorption and Introduces Phexxi as a Non-Oral Solution

August 19, 2024

Evofem Biosciences Announces Financial Results for the Second Quarter of 2024

August 13, 2024

OTCQB Venture Virtual Investor Conference Presentations Now Available for On-Demand Viewing

August 1, 2024

Watch the Evofem Biosciences, Inc. Presentation at the 8/1/2024 OTCQB Venture Virtual Investor Conference

August 1, 2024

Evofem Biosciences to Present at the OTCQB Venture Virtual Investor Conference on August 1st

July 24, 2024

Evofem Signs Phexxi® License Agreement for Middle East with Pharma 1

July 22, 2024

Aditxt and Evofem Amend and Restate Merger Agreement, Targeting September 30 Closing

July 16, 2024

Older news releases →

Calls

The 5 newest of 8 calls. Every call is listed under its year.

Decks

The 5 newest of 31 decks. Every deck is listed under its year.